ABOUT US
Unveiling our vision, mission, and values
Vision
Revolutionizing patient care with advanced in vivo imaging diagnostics, ensuring swift access to personalized treatments for a future of hope and healing.
Mission
At ABSCINT, our mission is to revolutionize HER2 cancer care by developing state-of-the-art in vivo imaging diagnostics. We are dedicated to leveraging the collective expertise of our dynamic team, employing groundbreaking science to accelerate the journey from diagnosis to tailored treatment.
Through unwavering commitment, we aim to empower the medical community, providing them with the tools to diagnose and select the right cancer treatment with confidence and resilience.
Values
- Expertise-Driven Innovation: Commitment to excellence and groundbreaking science, embracing challenges as opportunities for growth and pushing the boundaries of what’s possible.
- Collaborative Synergy: Thriving on open communication, teamwork and collaboration, working closely with nuclear medicine physicians and oncologists to ensure our diagnostics align seamlessly with clinical needs, fostering a common approach to patient care.
- Patient-Centric Focus: Prioritizing patient needs, providing faster access to the right treatment with compassion.
- Investor Partnership: Honoring investor trust, delivering results that exceed expectations for a mutually beneficial partnership.
Through these values, we aim to reshape HER2 cancer diagnostics, leaving an enduring impact on patients’ lives.
Board of Directors
Koen Dewaele
President of the Board
Karine Clauwaert
ABSCINT
Sara Vandenwijngaert
Qbic Venture Partners II
Marleen Limbourg
Noshaq Partners
Didier Allaer
Kazoku Gestion
Jacobus Boonen
Vrije Universiteit Brussel
Corentin Warnier
Trasis, Observer
Valentin Tonnel
Wallonie Entreprendre, Observer
Tom Smets
Qbic Venture Partners II, Observer
Marleen Keyaerts
Founders Feeder, Observer
Our Partners
